Bachem Reports Strong Sales Growth and Sustained High Profitability

Rhea-AI Summary

Bachem (OTC: BCHMY) reported group sales of CHF 695.1 million in 2025, up 14.8% (+19.2% in local currencies), and EBITDA of CHF 214.7 million (+21.8%), yielding an EBITDA margin of 30.9% (adjusted 28.6%).

The board proposes raising the dividend to CHF 0.90 per share. Investments totaled CHF 332.6 million in 2025 and CAPEX above CHF 400 million is planned for 2026. Outlook: sales growth of 35–45% in LC and an EBITDA margin in the low thirties (LC) for 2026.

Positive

• Sales +14.8% to CHF 695.1 million
• EBITDA +21.8% to CHF 214.7 million
• EBITDA margin at 30.9% (adjusted 28.6%)
• Net income +23.7% to CHF 148.8 million
• Investments of CHF 332.6 million in 2025
• 2026 outlook: sales growth 35–45% in local currencies

Negative

• One-time income of CHF 16.1 million boosted 2025 results
• Commercial ramp-up of Building K required to meet 2026 targets
• Planned CAPEX >CHF 400 million in 2026 increases capital intensity
• High sales concentration: CMC Development rose 29.7% to CHF 304.0 million

Bubendorf, Switzerland--(Newsfile Corp. - March 12, 2026) - Ad hoc announcement pursuant to Art. 53 LR

Bachem Reports Strong Sales Growth and Sustained High Profitability

• Group sales increase to CHF 695.1 million in 2025 (+14.8%, in local currencies +19.2%).
• EBITDA increases to CHF 214.7 million (+21.8%, in local currencies +32.6%).
• EBITDA margin lies at 30.9%. Adjusted for one-time effects of CHF 16.1 million, the EBITDA margin amounts to 28.6% and in local currencies 30.2%.
• Board of Directors proposes an increase in the dividend of CHF 0.05 to CHF 0.90 per share.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10552/288241_figure1.png

Anne-Kathrin Stoller, new CEO of Bachem, on the results of fiscal year 2025:

"We can look back on a year of strong sales growth and sustained high profitability. Demand for our products and services remains strong, and our order situation remains at a very high level. Through targeted operational improvements as part of our Operational Excellence initiatives, we were not only able to significantly increase the capacity of our existing facilities, but also further improve our cost structure. Another important milestone for the future was the successful completion of the inspection of Building K. Our continuous growth is both a reflection of the trust our customers place in us and the result of the outstanding performance of our teams worldwide.”

Group results

The Bachem Group (SIX: BANB) increased sales in Swiss francs by 14.8% to CHF 695.1 million in 2025. In local currencies (LC), sales increased by 19.2%.

Operating income before depreciation and amortization (EBITDA) increased by 21.8% to CHF 214.7 million (+32.6% in LC), which translates into an EBITDA margin of 30.9% (2024: 29.1%). In the reporting year, one-time income of CHF 16.1 million was realized primarily in connection with the Sisslerfeld site development and the sale of a building in the US that was no longer in operational use. These transactions are one-time effects and have a correspondingly positive impact on the 2025 results. Adjusted, the operating business shows an EBITDA margin of 28.6% (in LC 30.2%).

Operating income (EBIT) rose by 25.7% to CHF 167.3 million (+39.8% in LC). The EBIT margin in the reporting year increased to 24.1% (2024: 22.0%).

Net income grew to CHF 148.8 million (+23.7%) with a margin of 21.4% (2024: 19.9%).

Sales by product category

Bachem achieved sales of CHF 343.4 million (2024: CHF 327.0 million, +5.0%, in LC +8.2%) with commercial active ingredients (Commercial API). This was mainly due to a strong increase in sales of patent-protected peptides.

In the clinical medicines category (CMC Development), sales increased to CHF 304.0 million (2024: CHF 234.4 million, +29.7%, in LC +35.6%) driven by strong peptide-based development projects.

Business with research chemicals and specialty products (Research & Specialties) grew to CHF 47.7 million (2024: CHF 43.8 million, +8.8%, in LC +13.8%), among other things thanks to higher sales of peptides for use in diagnostics and cosmetics.

Investments and operational initiatives strengthen the production base 

Bachem successfully continued its comprehensive investment program to expand global production capacities in 2025. A total of CHF 332.6 million was invested in the 2025 reporting year. In addition to major projects such as Building K, a large portion of the funds was allocated to the modernization and further development of the entire site network.

The first phase of Building K (construction began in 2021) was successfully inspected by the Swiss Agency for Therapeutic Products (RHI) at the end of 2025. Commercial production will be ramped up gradually in 2026 while the second construction phase is completed. The successful ramp-up of commercial production in Building K is a key prerequisite for achieving the sales target in 2026.

Significant investments were also made at other Bachem sites. At the Vista site in the US, investments were made in additional capacity for large-volume production, complemented by the acquisition of an adjacent building for future site development. The Torrance site was further upgraded as part of a modernization program. In addition, investments were made in Vionnaz to secure the supply of key precursors.

For the planned additional production site in Sisslerfeld in Eiken, Switzerland, the fourth and fifth plots of land were acquired. In addition, the building application for a utility tunnel has been submitted to further support the long-term development of the site. 

Outlook

Bachem expects sales growth of between 35% and 45% in local currencies for the 2026 financial year. The EBITDA margin is expected to be in the low thirties in local currencies in 2026. The company plans CAPEX investments of more than CHF 400 million in 2026.

The complete Annual Report 2025 can be viewed and downloaded on the Bachem website:
https://www.bachem.com/about-bachem/investors-and-media/reports-and-presentations/

Financial Calendar

April 29, 2026             Annual General Meeting (business year 2025)

May 6, 2026               Payout date for dividend

July 30, 2026              Publication of Half-Year Report 2026

November 26, 2026    Capital Markets Day

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

For more information:

Media Patrick Barth Head Group Communications Tel.: +41 58 595 4522 Email: media@bachem.com

Investors Barbora Blaha Head Investor Relations Tel.: +41 58 595 0573 Email: ir@bachem.com

 

This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288241

FAQ

What were Bachem (BCHMY) full-year 2025 sales and growth?

Bachem reported CHF 695.1 million in sales for 2025, a 14.8% increase. According to the company, growth was +19.2% in local currencies, driven by peptide demand across commercial and clinical segments.

How did Bachem (BCHMY) profitability perform in 2025?

EBITDA reached CHF 214.7 million, up 21.8%, with a 30.9% margin. According to the company, adjusted EBITDA margin was 28.6% after excluding CHF 16.1 million of one-time income.

What dividend did Bachem (BCHMY) propose for 2025 and payout timing?

The board proposed increasing the dividend to CHF 0.90 per share. According to the company, the payout date is scheduled for May 6, 2026 following the April 29, 2026 AGM.

How much did Bachem (BCHMY) invest in 2025 and what are 2026 CAPEX plans?

Bachem invested CHF 332.6 million in 2025 and plans CAPEX of more than CHF 400 million in 2026. According to the company, funds supported Building K and global site upgrades.

What is Bachem's (BCHMY) 2026 sales and margin outlook?

Bachem expects sales growth of 35%–45% in local currencies for 2026 and an EBITDA margin in the low thirties (LC). According to the company, Building K ramp-up is key to achieving the target.

Which product segments drove Bachem's (BCHMY) 2025 growth?

Growth was led by Commercial API and CMC Development, with CMC Development rising to CHF 304.0 million. According to the company, strong peptide-based development projects underpinned the increase.